Page 2 - Olatec Therapeutics News Today

COVID-19 clinical trial pipeline constitutes 420+ key companies continuously working towards developing 520+ COVID-19 vaccines and drugs, analyzes DelveInsight LAS VEGAS, Nov. 8, 2022 /PRNewswire/

This study examines the risk of long COVID following mRNA vaccination, compared with no vaccination, in health care workers in Italy who had COVID-19 infection.

/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

MindMed Announces Chief Executive Officer Transition News provided by Share this article Share this article NEW YORK, June 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines, announces that J.R. Rahn, the Companys co-founder and chief executive officer, is stepping down as chief executive officer and a director, and that its chief ...

Phase III and is being developed by Kringle Pharma.  HGF was given an orphan drug designation for Acute Spinal Cord Injury by the Japanese Ministry of Health, Labour and Welfare in September 2019. In October 2019, GTX Medical and NeuroRecovery Technologies announced their merger to create a leading global company committed to developing novel neuromodulation therapies to improve people’s functional recovery with Spinal Cord Injuries. The merged entity will be known as GTX Medical BV. Th...

Heart failure, gout, COVID-19, melanoma Completed Phase 1 and Phase 1b in patients with heart failure and Phase 2a in patients with acute gout flares. A Phase 2 trial for people with moderate COVID-19 symptoms is ongoing, and the company is planning a Phase 2 trial in late-stage melanoma, along with an approved immunotherapy. Drugging the inflammasome For years after the inflammasome’s initial discovery, the search for drugs that target it yielded no promising leads, Cooper says. “Big phar...

This Viewpoint summarizes the pathophysiology and clinical features of atherosclerotic plaque erosion as an underlying mechanism of acute coronary syndromes (AC

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience News provided by Share this article Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Office...

Published: Dec 29, 2020   The data are published in the Proceedings of the National Academy of Sciences Results suggest a potential therapeutic benefit for dapansutrile in patients with neuroinflammatory diseases, e.g., Alzheimer’s Disease Preclinical results encourage clinical research with dapansutrile in Alzheimer’s Disease to investigate therapeutic effect in humans   NEW YORK--(BUSINESS WIRE)-- Olatec Therapeutics LLC (“Olatec”) today announced the publication of data demons...